It is indeed an opportune time for Prestwick to have a company leader who is described as having "experience in managing regulatory processes" by Prestwick's board of directors. Hopefully, he will be successful in gaining FDA approval for tetrabenazine. Read the press release on the company's website.

The U.S. Food and Drug Administration (FDA) will soon be deciding whether to approve tetrabenazine. Drs. LaVonne Veatch Goodman and Nathan Goodman put the tetrabenazine story into the broader context of providing rapid access to drugs for people with serious illnesses like Huntington's.

The Hereditary Disease Foundation, led by Dr. Nancy Wexler, is collecting letters from Huntington's people that will be forwarded to the FDA. See the announcement on the HDF website.

There is little doubt that tetrabenazine improves chorea in many patients, and there is strong evidence that the side effects can usually be controlled. Dr. LaVonne Veatch Goodman argues that Huntington's patients and their doctors should have the right to decide whether to use this drug.

In a report reviewing over two decades of clinical experience with tetrabenazine and depression, doctors from Baylor College of Medicine report promising results in the journal Clinical Neuropharmacology. Dr. LaVonne Veatch Goodman summarizes the findings and explains why this is important for Huntington’s people.

Clinical trials are starting for a new Huntington's drug called Dimebon. This news report by Linda Miller and Dr. LaVonne Veatch Goodman provides background on the drug and information on the trial including where to sign up.

Researchers from the University of Iowa School of Medicine report on the frequency of severe depression across the stages of Huntington’s disease. Dr. LaVonne Veatch Goodman summarizes the findings and stresses the need for treatment of this serious component of HD with drugs that are available now.

In two separate reports, researchers from the University of Indiana and Imperial College in England report promising results on a potential new biomarker for Huntington's. With more work, this could lead to shorter clinical trials for HD drugs. Summary by Dr. LaVonne Veatch Goodman.

Gene Veritas, author of the Cure HD blog, offers this eloquent tribute to his mother and his ongoing struggle with Huntington's. Gene describes himself as "a middle-aged writer living at risk for Huntington's disease whose passion in life is to stop HD and other neurological diseases from devastating individuals and their families". Reprinted by permission from Gene's blog.

In this editorial, Dr. LaVonne Veatch Goodman draws an analogy between passengers on a sinking ship who can choose between going down with the ship or leaping into a lifeboat, and Huntington's people faced with promising but unproven treatments.